Radiotherapy leads to a significant increase in CCL2 production by pancreatic ductal adenocarcinoma cells and recruitment of TAMs, and neutralizing anti-CCL2 antibody selectively inhibits radiotherapy-dependent recruitment of TAMs and delays tumor growth in combination with radiotherapy [54]. This evidence concerns the gene CCL2 and neoplasm.